BACKGROUND: African Americans with genotype 1 chronic hepatitis C attain a sustained virologic response (SVR) at only approximately one-half the rate of whites after peginterferon and ribavirin treatment. The serum concentration of 25-hydroxyvitamin D [25(OH)D] has recently been established as a predictor of treatment response. Therefore, the low serum concentrations of 25(OH)D found among African Americans may contribute to the low response rate; however, to our knowledge, none of the studies of vitamin D in chronic hepatitis C treatment have included a significant number of black patients. OBJECTIVE: The objective was to compare the relation between the 25(OH)D concentration and genotype 1 chronic hepatitis C treatment response in African Americans with that in whites. DESIGN: This cross-sectional analysis included 106 African American and 65 white patients with genotype 1 chronic hepatitis C. RESULTS: Consistent with previous studies, we found that the SVR rate in the white patients increased significantly with an increasing serum concentration of 25(OH)D [SVR rates were 20%, 46%, and 70% for 25(OH)D serum concentrations <20, 20-35, and >35 ng/mL, respectively; P-trend = 0.008]; however, there was no relation between the SVR rate and 25(OH)D serum concentration in the African American patients [SVR rates were 32%, 28%, and 33% for 25(OH)D serum concentrations <20, 20-35, and >35 ng/mL, respectively; P-trend = 0.832]. We also found an analogous racial difference in the relation between the extent of liver fibrosis and the 25(OH)D concentration. CONCLUSION: Racial differences in vitamin D physiology or race-specific factors that modify the effects of vitamin D may affect the immune response to genotype 1 hepatitis C virus.
BACKGROUND: African Americans with genotype 1 chronic hepatitis C attain a sustained virologic response (SVR) at only approximately one-half the rate of whites after peginterferon and ribavirin treatment. The serum concentration of 25-hydroxyvitamin D [25(OH)D] has recently been established as a predictor of treatment response. Therefore, the low serum concentrations of 25(OH)D found among African Americans may contribute to the low response rate; however, to our knowledge, none of the studies of vitamin D in chronic hepatitis C treatment have included a significant number of black patients. OBJECTIVE: The objective was to compare the relation between the 25(OH)D concentration and genotype 1 chronic hepatitis C treatment response in African Americans with that in whites. DESIGN: This cross-sectional analysis included 106 African American and 65 white patients with genotype 1 chronic hepatitis C. RESULTS: Consistent with previous studies, we found that the SVR rate in the white patients increased significantly with an increasing serum concentration of 25(OH)D [SVR rates were 20%, 46%, and 70% for 25(OH)D serum concentrations <20, 20-35, and >35 ng/mL, respectively; P-trend = 0.008]; however, there was no relation between the SVR rate and 25(OH)D serum concentration in the African American patients [SVR rates were 32%, 28%, and 33% for 25(OH)D serum concentrations <20, 20-35, and >35 ng/mL, respectively; P-trend = 0.832]. We also found an analogous racial difference in the relation between the extent of liver fibrosis and the 25(OH)D concentration. CONCLUSION: Racial differences in vitamin D physiology or race-specific factors that modify the effects of vitamin D may affect the immune response to genotype 1 hepatitis C virus.
Authors: Michelle Braun; Cristina Palacios; Karin Wigertz; Lisa A Jackman; Rebecca J Bryant; Linda D McCabe; Berdine R Martin; George P McCabe; Munro Peacock; Connie M Weaver Journal: Am J Clin Nutr Date: 2007-06 Impact factor: 7.045
Authors: Hari S Conjeevaram; Michael W Fried; Lennox J Jeffers; Norah A Terrault; Thelma E Wiley-Lucas; Nezam Afdhal; Robert S Brown; Steven H Belle; Jay H Hoofnagle; David E Kleiner; Charles D Howell Journal: Gastroenterology Date: 2006-08 Impact factor: 22.682
Authors: Hari S Conjeevaram; David E Kleiner; Jay E Everhart; Jay H Hoofnagle; Steven Zacks; Nezam H Afdhal; Abdus S Wahed Journal: Hepatology Date: 2007-01 Impact factor: 17.425
Authors: Robert J Fontana; David E Kleiner; Richard Bilonick; Norah Terrault; Nezam Afdhal; Steven H Belle; Lennox J Jeffers; Darmendra Ramcharran; Marc G Ghany; Jay H Hoofnagle Journal: Hepatology Date: 2006-10 Impact factor: 17.425
Authors: D L White; S Tavakoli-Tabasi; F Kanwal; D J Ramsey; A Hashmi; J Kuzniarek; P Patel; J Francis; H B El-Serag Journal: Aliment Pharmacol Ther Date: 2013-05-26 Impact factor: 8.171
Authors: Erikka Loftfield; Thomas R O'Brien; Ruth M Pfeiffer; Charles D Howell; Ron Horst; Ludmila Prokunina-Olsson; Stephanie J Weinstein; Demetrius Albanes; Timothy R Morgan; Neal D Freedman Journal: PLoS One Date: 2016-11-10 Impact factor: 3.240
Authors: Sami A Gabr; Ahmad H Alghadir; Ahmed A Allam; Jamaan Ajarem; Ghada Al-Basher; Mostafa A Abdel-Maksoud; Ayman A Ghfar; Alaa Aboud Journal: Clin Interv Aging Date: 2016-05-04 Impact factor: 4.458